Arrayit Corporation. Stock symbol (ARYC).
Arrayit corporation is the new company profile for January 30th 2012. Redhotstocks llc and all officers own 64,000 shares of ARYC purchased in the open market for .16 , .19 , and .20 . Redhotstocks and all officers plan to continue to buy the stock in the next 6 months.
The following information is a breakdown of the company and a few highlights of why Redhotstocks.com believes the company’s early detection cancer tests will save a lot of lives and thus making the company significantly more valuable than todays current share price.
Redhotstocks LLC and all operating officers have no affiliation with any companies mentioned and have not been paid any cash or stock. Redhotstocks.com remains dedicated to bringing the most provectus companies to the forefront of the investment community that are doing their part to save humanity and create a better world for tomorrow.
Business Description
Arrayit leads professionals in the microarray industry by developing, manufacturing and marketing life science tools and integrated laboratory platforms for the analysis of genetic variation, biological function, and diagnostics. Arrayit provides it specialized equipment, tools, microarray manufacturing services to more than 10,000 research laboratories, pharmaceutical companies, academic institutions, clinical research organizations, government agencies and biotechnology companies around the globe.
Arrayit competes with large and small, public and private companies. The industry has been historically dominated by Affymetrix which achieved strong market penetration by being the first public company to commercialize and promote microarray applications. A more recent entry to the market, Illumina, has taken significant market share from Affymetrix. However, both competitors face mid to long term scientific and technological challenges because they are limited by what they can deposit onto a microarray–DNA. Arrayit’s patented printing technology can deposit any kind of molecule into a microarray, including DNA, proteins, antibodies, diagnostic elements and other compounds. These next generation microarrays represent the largest growth opportunity in the industry. Arrayit has a long-term advantage in its unique line of personal and high throughput microarray printers, highest sensitivity microarray scanners, top quality consumables, patented diagnostic methods, collaborative corporate culture, and competitive pricing.
ARYC Security Details
Share Structure
Market Value1 $7,814,484 a/o Jan 30, 2012
Shares Outstanding 26,946,496 a/o Sep 30, 2011
Float 11,607,500 a/o Aug 12, 2011
Authorized Shares 480,000,000 a/o Jun 30, 2011
Par Value 0.001
Shareholders
Shareholders of Record 377 a/o Mar 31, 2010
Contact Info
524 East Weddell Drive
Sunnyvale, CA 94089
Website: http://www.arrayit.com
Phone: 408-744-1711
Email: arrayit@arrayit.com
The Sunnyvale, Calif.-based array products and services provider intends to distribute to its existing shareholders its 78.18 percent interest in Arrayit Diagnostics as a stock dividend. The distribution date and further details are expected to be announced early in the first quarter of 2012. Upon gaining independence, Arrayit Diagnostics expects to be listed on the Over-the-Counter Bulletin Board securities market in the US.
Paul Haje, Arrayit’s vice president of sales and marketing, told BioArray News this week that the company is spinning off Arrayit Diagnostics in order to attract investments that will facilitate the regulatory clearance and commercialization of its tests, the farthest along of which is OvaDx, an array-based diagnostic for early-stage ovarian cancer.
“We have investors who really want to make a focused investment in Arrayit Diagnostics, and who want to be involved in the milestones associated with that,” Haje said.
Haje said that Arrayit Diagnostics is in negotiations with a potential investor — a company that is a “household word” and “wants to get into microarrays and life sciences” — but he declined to name the interested party.